Maze Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(24,208) | $(32,786) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 444 | 684 |
| Stock-based compensation expense | 7,109 | 3,226 |
| Non-cash lease expense | 831 | 767 |
| Accretion of discounts on marketable securities, net | (2) | — |
| Amortization of debt discount and debt issuance costs | 371 | — |
| Other items, net | 18 | 18 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (20,000) | — |
| Prepaid expenses and other current assets | 404 | (474) |
| Other assets | (605) | 338 |
| Accounts payable | 2,212 | 579 |
| Accrued expenses and other liabilities | (4,066) | (1,063) |
| Operating lease liabilities | (915) | (805) |
| Long-term liabilities | (706) | — |
| Net cash used in operating activities | (39,113) | (29,516) |
| Investing activities | ||
| Purchases of marketable securities | (23,632) | — |
| Maturities of marketable securities | 30,000 | — |
| Purchases of property and equipment | (93) | (299) |
| Net cash provided by (used) in investing activities | 6,275 | (299) |
| Financing activities | ||
| Proceeds from debt issuance, net | 39,401 | — |
| Payment of debt issuance costs | (886) | — |
| Proceeds from exercise of stock option awards | 4,079 | 126 |
| Payment of deferred offering costs | (226) | — |
| Payment of offering costs for private placement | (11) | — |
| Proceeds from initial public offering, net of offering costs paid | — | 127,752 |
| Payment of success fee derivative | — | (500) |
| Net cash provided by financing activities | 42,357 | 127,378 |
| Net increase in cash, cash equivalents and restricted cash | 9,519 | 97,563 |
| Cash, cash equivalents and restricted cash at beginning of the period | 190,335 | 197,900 |
| Cash, cash equivalents and restricted cash at end of the period | $199,854 | $295,463 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $6 | $48 |
| Debt issuance costs recorded in accounts payable and accrued expenses | $53 | $— |
| Deferred offering costs recorded in accrued expenses | $441 | $— |
| Reconciliation to cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $198,766 | $294,374 |
| Restricted cash | 1,088 | 1,089 |
| Total cash, cash equivalents and restricted cash | $199,854 | $295,463 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.